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16 Abstract 
17 RNA interference (RNAi) based therapeutics are considered an endogenous 
18 mechanism for modulating gene expression. In addition, microRNAs (miRNAs) may 
19 be tractable targets for the treatment of Chronic Obstructive Pulmonary Disease 
20 (COPD). In this study miR146a was adsorbed onto poly (glycerol adipate-co-ω- 
21 pentadecalactone), PGA-co-PDL, nanoparticles (NPs) to reduce target gene IRAK1 
22 expression. NPs were prepared using an oil-in-water single emulsion solvent 
23 evaporation method incorporating cationic lipid dioleoyltrimethylammoniumpropane 
24 (DOTAP). This resulted in NPs of 244.80±4.40 nm at 15 % DOTAP concentration, zeta 
25 potential (ZP) of +14.8±0.26 mV and miR-146a (40 µg/ml) maximum adsorption onto 
26 15 % DOTAP NPs was 36.25±0.35 µg per 10 mg NP following 24 h incubation. Using 
27 the MTT assay, it was observed that over 75 % at 0.312 mg/ml of A549 cells remained 
28 viable after 18 h exposure to cationic NPs at a concentration of 1.25 mg/ml. 
29 Furthermore, the in vitro release profile of miR-146a from loaded NPs showed a 
30 continuous release up to 77 % after 24 h. Internalization of miR-146a loaded cationic 
31 NPs was observed in A549 cell lines using fluorescence and confocal microscopy. The 
32 miR146a delivered as miR-146a-NPs had a dose dependent effect of highest NPs 
33 concentrations 0.321 and 0.625 mg/ml and reduced target gene IRAK1 expression to 
34 40 %. In addition, IL-8 promoter reporter output (GFP) was dampened by miR-146a- 
35 NPs. In conclusion, miR-146a was successfully adsorbed onto PGA-co-PDL-DOTAP 
36 NPs and the miR-146a retained biological activity. Therefore, these results 
37 demonstrate the potential of PGA-co-PDL NPs as a delivery system for miR-146a to 
38 treat COPD. 
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84 1. Introduction 
85 Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
86 mortality and is currently the fourth leading cause of death in the world and predicted 
87 to become the third leading cause of chronic illness and death by 2030 [1]. The World 
88 Health Organization (WHO) estimated that more than 3 million people died of COPD 
89 in 2012, which is equivalent to 6 % of all deaths globally that year [1]. Moreover, the 
90 Global Initiative on Obstructive Lung Disease (GOLD) indicated the disease is more 
91 prevalent among males than females [2]. 
92 Current therapeutic strategies to reduce COPD (bronchodilators, antibiotics, 
93 inhaled corticosteroids and oxygen) [3] have not been shown to delay or correct the 
94 long term advancement of COPD [2]. 
95 Mature microRNAs (miRNAs) are small noncoding RNA molecules (≈22 
96 nucleotides long) that downregulate gene expression, first through acute translational 
97 repression but subsequently by steady-state mRNA destabilisation [4]. Therapeutic 
98 interventions based on modulation of miRNA levels have emerged as a tractable 
99 approach for clinical intervention in respiratory diseases [5-7]. In particular, miR-146a 
100 has been linked to COPD pathogenesis [8, 9]. The ability of miR-146a to downregulate 
101 the interleukin 1 receptor (IL-1R) and Toll-like receptor (TLR) signalling components 
102 IL-1 receptor-associated kinase (IRAK1) and tumour necrosis factor (TNF) receptor- 
103 associated factor (TRAF6) supports negative feedback regulation of IL-1β, IL-6 and 
104 IL-8 [10, 11]. However, one of the main concerns regarding targeting inflammatory 
105 lung disease is that upon delivery of the naked, negatively charged miRNAs to the site 
106 of action, the molecules cannot cross the anionic cell membranes [12]. 
107 Nanoparticles (NPs) have potential to overcome this problem and altering the 
108 surface charge to be cationic can enhance the interaction with negative miRNA and 
109 particle uptake into cells [13]. NPs prepared from traditional biodegradable polymers 
110 such as poly (lactic-co-glycolic acid) (PLGA) or poly (glycerol adipate-co-ω- 
111 pentadecalactone) (PGA-co-PDL) can be used for gene delivery and specific cell 
112 targeting by coating the NPs with cationic materials [14] or incorporating cationic 
113 surfactants [13]. Nucleic acids can bind and adsorb onto the cationic NPs via 
114 electrostatic interactions. The difficulty in loading of miRNA into NPs can be attributed 
115 to the hydrophobic nature of NPs and the absence of electrostatic interaction between 
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116 miRNA and NPs. Studies revealed that additionally attaching molecules such as 
117 chitosan or cationic lipids such as dioleoyltrimethylammonium propane (DOTAP) 
118 promote siRNA transfection efficacy [15]. These cationic additives can be added to the 
119 NPs’ surface pre or post formation [16]. 
120 PGA-co-PDL NPs have previously been investigated for the delivery of proteins 
121 and vaccines either by encapsulation of the molecules within the particle or adsorption 
122 to the surface [17-20]. In this study, we optimised the formulation of the NPs with 
123 surface adsorbed miR-146a for delivery to lung epithelial cells and then evaluated the 
124 toxicity, in vitro release, cell uptake, and biological activity. 
125 
 
126 2. Materials and Methods 
127 2.1. Materials 
128 Poly (vinyl alcohol) PVA, Mw of 13- 23 kDa 87-89% hydrolysed was purchased 
129 from Clariant GmbH, Frankfurt am Main, Germany), Novozyme 435 (a lipase from 
130 Candida antartica immobilized on a microporous acrylic resin) from Biocatalytics, USA 
131 and DOTAP from Avanti Polar lipids, Alabaster, AL, USA. Solvents were purchased 
132 from Fischer chemicals (Fischer Scientific, UK). RPMI-1640 medium with L-glutamine 
133 and NaHCO3, thiazoly blue tetrazolium bromide (MTT), Nile red and RNase-free 
134 diethyl pyrocarbonate (DEPC) water were purchased from Sigma Aldrich, UK. A 
135 synthetic miR-146a mimic with a FAM-label on the sense 5’ FAM- 
136 CCGGGCAAUUCAGUUUCUACA-dTdT-3’, was purchased from Eurogenetec, UK 
137 with the sequence: sense 5’ FAM-CCGGGCAAUUCAGUUUCUACA-dTdT-3’, 
138 antisense 5’ dTdT-GGCCCGUUAAGUCAAAGAUGU-3’. 
139 
140 2.2. Methods 
141 2.2.1.Nanoparticle preparation and miRNA adsorption 
142 PGA-co-PDL NPs were prepared using an oil-in-water (o/w) single emulsion 
143 method, incorporating 0.4 mg Nile Red dye in the inner organic phase 
144 (dichloromethane, DCM) for visualization experiments aqueous phase contained 10 
145 %   w/v   poly (vinyl  alcohol), (PVA) as previously described [13]. Indicated 
146 concentrations of DOTAP (5, 10, 15, 20, and 25 % w/w of the polymer) were added to 
147 the organic phase to prepare cationic NPs. The FAM-labelled miR-146a mimic (40, 
148 30, 20 and 10 µg, respectively) was added to 1 ml solution of RNase free water 
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149 containing 10 mg of NPs (to obtain a final NP:miRNA weight ratio of 250:1) and mixed 
150 using a HulaMixer Sample Mixer (Life Technologies, UK) at 20 rpm and 25 °C at 
151 staggered time points (0.5, 1, 2, 4 and 24 h). After adsorption, RNase free water was 
152 added to a total volume of 4 ml prior to separation of free miR-146a from the adsorbed 
153 miR-146a by ultracentrifugation at 35000 x g, for 40 min at 4 °C using an Optima L-80 
154 Ultracentrifuge (Beckman, UK). 
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2.2.2. Particle size and zeta potential 
157 The mean particle size and polydispersity index (PDI) of the NPs were analysed 
158 by dynamic laser scattering, and the surface charge of the particles determined by 
159 analysis of the zeta-potential using a Zetasizer Nano ZS, Malvern Instruments Ltd, 
160 UK. The NPs (10 mg) were diluted with 4 ml distilled water and 1 ml of the diluted 
161 sample was loaded into a measuring cuvette. 
162  
163 2.2.3. miRNA adsorption characterisation 
164 The concentration of adsorbed miR-146a was determined indirectly from the 
165 difference in miR-146a concentration before and after loading by UV absorbance at 
166 260 nm using a NanoDrop 2000C (Thermo Fisher Scientific, and USA). Furthermore, 
167 the concentration of FAM labelled miR-146a was determined by fluorescence using a 
168 plate reader (CLARIOstar®) at λex: 495 nm; λem; 520 nm. In both cases, a calibration 
169 curve was generated using known concentrations of miR-146a. 
170  
171 2.2.4. In vitro release 
172 The miR-146a-adsorbed PGA-co-PDL NPs (10 mg) were suspended in 4 ml 
173 PBS (pH 7.4) and incubated at 37°C with rotation at 20 rpm on a HulaMixer, samples 
174 were centrifuged (Beckman L-80 Ultracentrifuge, UK) at 35000 x g for 40 min and 1 
175 ml of supernatant was collected for quantification. The particles were re-suspended in 
176 1 ml PBS and incubation resumed. The absorbance of the supernatant was measured 
177 on a Nanodrop spectrophotometer at 260 nm. The amount of released miR-146a was 
178 calculated as a percentage of cumulative released miR-146a to the total amount of 
179 adsorbed miR-146a. 
Cumulative miR - 146a released 
350 
351 
352 
353 
180 % Cumulative miR - 146a released = 
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miR - 146a loaded 
×  100
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181 The % cumulative miR-146a release was assessed using zero order, first order and 
182 Higuchi’s square root plot release models. The correlation coefficient was calculated 
183 from the following graphical representations, zero order: % cumulative miR-146a 
184 release versus time; first order: log % cumulative miR-146a remaining versus time; 
Higuchi: % cumulative miR-146a release versus square root of time. 
2.2.5. Cell culture and toxicity studies 
187 Human alveolar adenocarcinoma A549 cells ( ATCC, LGC Standards, Europe) 
188 were maintained at 37°C and 5 % CO2 in RPMI-1640 medium with 100 U/ml penicillin, 
189 100 µg /ml streptomycin, 2 mM L-glutamine and 10 % fetal bovine serum (FBS). 
190 Cytotoxicity was determined in vitro using the MTT assay. Cells were seeded in 96 
191 well plates in growth medium at a density of 1.2 x 105 cells per well. After 18 h (80 % 
192 confluence), the cells were incubated for a further 24 h with 100 µl of pre-mixed freshly 
193 prepared cationic NPs and non-cationic NPs (control) at range of concentrations (0 - 
194 2.5 mg/ml), and 10% dimethyl sulfoxide (DMSO) as a positive control. The medium 
195 was removed after 18 h and 40 µl of the MTT solution (5 mg/ml in PBS) added to each 
196 well for 2 h at 37°C, followed by removal of MTT medium and the formazan dissolved 
197 in 100 µl DMSO. The absorbance was measured at 570 nm and the cell viability 
198 percentage calculated as the absorbance ratio between NPs treated and non-treated 
199 cells (control). 
 
200 
201 2.2.6. Cell Imaging 
202 Cells (5 x 105 cells per well) were seeded in an 8 well chambered slide (Fisher 
203 Scientific, UK) and incubated overnight (37°C, 5 % CO2). Culture media was replaced 
204 with 500 µl of FAM-labelled miR-146a-NPs and Nile Red labelled NPs in serum free 
205 medium for 1 h. Cells were then washed with PBS and fixed using 4 % 
206 paraformaldehyde (PFA), or ice-cold (-20°C) 100 % methanol was used for 15 min. 
207 Permeabilization of the PFA-treated samples was performed with 0.1 % Triton-X 100 
208 for 10-15 min at room temperature. Nuclear counter-staining was performed with 1 
209 µg/ml DAPI for 5 min. Confocal images were acquired using a Zeiss LSM 710 confocal 
210 laser scanning microscope equipped with an argon ion laser. Using the 488 nm laser 
211 line for FAM labelled miR-146a and 543 nm line Nile Red labelled NPs. 
212 
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213 2.2.7. Semi-quantitative reverse transcriptase PCR 
214 Cells (3.8 x 105 cells per well) were incubated in serum free medium with miR- 
215 146a-NPs for 1 h. The miR-146a-NPs mixture was replaced with complete medium 
216 and the cells incubated for 24 h. Total RNA was extracted using the RNeasy Mini kit 
217 according to the manufacturer’s instructions. Reverse transcription for cDNA 
218 generation was performed on 200 ng RNA using miScript reagents (Qiagen, 
219 Manchester, UK). Levels of IRAK1 transcripts, were assessed using RT2 qPCR Primer 
220 Assays in 20 µl reactions composed of 10 µl SYBR Green PCR master mix, 2 µl 
221 primers, 2 µl diluted cDNA and water to 20 µl. The reactions were amplified for three- 
222 step method. Expression was normalised to glyceraldehyde-3-phosphate 
223 dehydrogenase (GAPDH) using the 2− ∆∆Ct method [21], SYBR Green PCR reagents 
224 and PCR primers were purchased from Qiagen (Manchester, UK). 
225 
226 2.2.8. Immunoblotting: Western blots 
227 Cells (3.8 x 105 cells per well) were seeded on a 6 well plate. After 24 h growth, 
228 the cells were incubated in serum free medium with 1 ml of pre-mixed freshly prepared 
229 miR146a-NPs at range of concentrations (0 – 0.625 mg/ml) for 1 h. The miR-146a- 
230 NPs was then replaced with complete medium and the cells incubated for 24 h and 48 
231 h respectively. The cells were rinsed with PBS, and lysed on ice by replacing the 
232 culture medium in RIPA buffer containing 150 mM sodium chloride, 1 % Triton X-100, 
233 0.5 % sodium deoxycholate, 0.1 % sodium dodecyl sulphate (SDS), 50 mM Tris PH 
234 8.0, sodium orthovandate and protease inhibitor tablet (Roche). The protein extract 
235 was determined using BCA assay (Sigma, UK). Samples (4 parts) were diluted with 
236 an equal volume of 1 part Laemmli buffer (0.5 M Tris-HCL PH 6.8, glycerol, SDS, 0.25 
237 % bromophenol blue, B-mercaptoethanol) and boiled for 5 min at 95 °C. Protein lysate 
238 (20 µg for each lane) were resolved on 12 % precast gel (Bio-Rad, UK) and transferred 
239 to nitrocellulose membranes in Tris-glycine buffer with 20 % methanol. Following 
240 transfer, membranes were blocked for 1 h at RT in 5 % fat free milk in TBST (TBS and 
241 Tween-20)  before  probing  overnight  at  4°C  with  antibodies  anti-IRAK1 (1:1000, 
242 Abcam), β-Actin (1:1000,ThermoFischer). Membranes were washed three times in 
243 TBST then incubated with horseradish Peroxidase conjugated secondary antibodies 
244 (1:5000, sigma) for 1 h at room temperature. Membranes were subsequently washed 
245 three times and exposed in a chemiluminescence Pierce ECL reagents (Thermo 
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246 Fisher,UK) according to manufacturer’s protocol. Densitometry was performed using 
247 ImgaeJ software, and protein of interest values were used to normalize against β-Actin 
248 values. 
249 
250 2.2.9 IL-8 Promoter Reporter assay 
251 Cells (5 x 105 cells per well ) were seeded on an 8 well chambered slide (Fisher 
252 Scientific, UK) and incubated for 24 h prior to transfection. Transfections were 
253 performed using Lipofectamine 3000 reagent following the manufacturer’s protocol 
254 (Life technology, UK) in serum free DMEM and a total amount of 0.5 µg of DNA per 
255 well was used. The DNAs used were pIL8/d2EGFP and pDsRED mono promoters, 
256 kind gifts from Professor Endre Kiss-Toth (University of Sheffield, UK). The cells were 
257 transfected for 6 h and then washed twice with PBS. A prepared mixture of unlabelled 
258 miR146a-NPs (100 µl) was added and incubated for 1 h. After this cells were washed 
259 twice in PBS then, cells were stimulated with 1 ng/ml IL-1β or TNFα and incubated for 
260 further 6 h. Cells were washed with PBS and subsequently fixed in -20 °C methanol 
261 and images acquired on an Olympus BX51 Fluorescent microscope. 
262 
263 2.2.10. Statistical analysis 
264 The experiments were performed in triplicate and data is presented as mean ± 
265 standard deviation (SD) unless stated. Statistical differences were performed by One- 
266 way analysis of variance (ANOVA) using Minitab® with the Tukey’s comparison at 
267 value p < 0.05. 
268 
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272 NPs (+/- DOTAP) were prepared using a single emulsion solvent evaporation 
273 method by adding the DOTAP, if relevant, in the organic phase at different DOTAP 
274 and PGA-co-PDL weight ratios. The data presented in this study indicate that PGA- 
275 co-PDL mixed with DOTAP formed cationic NPs using 10 % to 25 % (w/w) DOTAP. It 
276 was noted that increasing the concentration of DOTAP decreased particle size and 
277 caused the zeta potential to become more positive (Fig. 1A). Varying the concentration 
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278 of DOTAP incorporated into the PGA-co-PDL NPs resulted in a change in particle size 
279 from 266.10±20.80 nm at 0 % (w/w) DOTAP to 197.90±1.70 nm at 20 % (w/w) DOTAP 
280 and, a change in surface charge from -18.9±0.9 mV to +16.7±0.1 mV that varied 
281 according to DOTAP concentration (Fig. 1B).  
282 However, there was little change in particle properties from 15 % to 20 
283 % (w/w), so given the increased cost and toxicity of using higher DOTAP 
284 concentrations, 15 % (w/w) DOTAP was chosen for all future work and was selected 
285 for the subsequent miR-146a adsorption studies. 
286 miR-146a loaded cationic NPs (miR-146a-NP), showed no change in particle 
287 size compared to unloaded NPs (244.8±4.4 nm and 242.4±0.3 nm respectively). The 
288 charge after adsorption of miR-146a ranged between (+5.9 mV to +11.1 mV) for miR- 
289 146a NPs compared to +14.8 mV for unloaded NPs, showing the miR-146a loaded 
290 NPs were still positively charged. Furthermore, the reduction in zeta potential 
291 confirmed the miR-146a was adsorbed. 
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3.1.2. miR-146a adsorption 
296 The 15 % (w/w) DOTAP NPs were used to study miR-146a adsorption by first 
297 using a fixed miR-146a concentration (40 µg/ml) at different time points 0.5, 1, 2, 4 
298 and 24 h (Fig. 1C). After 0.5 h, 12.05 ± 1.3 µg of miR-146a (40 µg/ml) was adsorbed 
299 on 10 mg NPs. The maximum miR-146a adsorption was 36.25±0.35 µg miR-146a per 
300 10 mg NPs after 24 h. Beyond 2 h there was no significant difference in miR-146a 
301 adsorption with a maximum of 32.25±2.0 µg miR-146a per 10 mg NPs (p <0.05, 
302 ANOVA/ Tukey’s comparison). 
303 Furthermore, adsorption of miR-146a at different concentrations with a fixed 
304 time of 2 h was investigated. As shown in (Fig. 1D) over 75 % of miR-146a was 
305 adsorbed at concentrations of 20, 30 and 40 µg miR-146a. The positively charged NPs 
306 attract the negatively charged miR-146a by electrostatic interaction. Therefore, the 
307 results indicate that 15 % (w/w) DOTAP NPs can be effectively adsorbed with miR- 
308 146a. Confirmation that the miR-146a was associated with the NPs was achieved 
309 using fluorescence microscopy, which indicated the fluorescently labelled NPs (Nile 
310 Red dye) with labelled FAM-miR-146a (green) (Fig. 2). 
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311 
312 3.2. In vitro release and cytotoxicity 
313 The In vitro release profile of the miR-146a -loaded NPs (40 µg/ml) showed that 
314 the miR-146a release could be divided into stages (Fig. 3). The miR-146a was initially 
315 rapidly released in the first 4 h with 51±1.5 % cumulative release. Followed by a 
316 second stage during which the miR-146a was continually released between 4 h up to 
317 24 h, providing a cumulative release of 77±1.5 %. The correlation coefficient (r2) of 
318 miR-146a release from NPs was 0.743 (zero order), 0.441 (first order) and 0.932 
319 (Higuchi). The Higuchi diffusion model had the best correlation, hence, the release of 
320 the miR-146a from NPs seems to be a diffusion-limited process. 
321 To assess the toxicity profile of the PGA-co-PDL NPs with DOTAP coated NPs, 
322 15 % (w/w) DOTAP particles investigated for toxicity equivalent in size to non-loaded 
323 NPs. Blank cells (control) had 100 % cell viability, whereas cell viability at 1.25 mg/ml 
324 were around 90 % (unloaded NPs) that decreased to 65 % (15 % DOTAP NPs) (Fig. 
325 4), indicating the NPs appear to cause cell death with an increase in concentration 
326 after 18 h exposure [22, 23]. 
327 
328 3.3. Cellular uptake 
329 To visualise the cellular uptake of the NPs for delivery to A549 cells, NPs 
330 encapsulating Nile red dye were prepared and added to A549 cells. The NPs were 
331 observed around the nucleus and in the cytoplasm, in large populations of cells and 
332 single cells, indicating that the NPs were taken up by the cells (Fig. 5 A–C: 
333 fluorescence and D–F: confocal). 
334 Furthermore, to visualize the intracellular uptake of FAM-labelled miR-146a-NPs for 
335 delivery to A549 cells, FAM-labelled miR-146a-NPs were prepared and exposed to 
336 A549 cells. Cells were stained with DAPI, and particles were distributed differentially 
337 across a population of cells with a clear variation (Fig. 6 A–C: fluorescence). The same 
338 results were obtained with a single cell where the particles can be observed around 
339 the nuclei and cytoplasm (Fig. 6 D–F: confocal). 
340 
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341 3.4. Effect of miR-146a-loaded NPs on target gene, protein 
342 expression and reporter assay 
343 To confirm miR-146a-NP function, the expression of the target genes IRAK1 
344 was assessed in A549 cells. Analysis of transcript levels showed that miR-146a 
345 delivered via NPs (miR-146a mimic) and the highest NPs concentrations led to 
346 suppression of IRAK1 to 40 %, compared with untreated cells (Fig. 7A). The 
347 expression of IRAK1 was normalised to GAPDH expression. 
348 To confirm the downregulation of IRAK1 occurred at the protein levels, miR- 
349 146a-loaded NPs were applied to A549 cells and lysates evaluated by immunoblotting 
350 (Fig. 7B). The miR-146a-NPs reduced IRAK1 protein levels in A549 cells after 24 h 
351 and 48 h treatment. The decrease in protein levels occurred in a dose dependent 
352 manner compared to untreated cells, suggesting that IRAK1 protein levels reduced in 
353 response to miR-146a-NPs. 
354 To determine miR-146a-NPs biological function, the IL-8 promoter reporter 
355 assay was used. The pIL-8 promoter- GFP reporter was transfected into A549 cells, 
356 which express the functional IL-1 receptors [24]. The promoter’s response after IL-1β 
357 stimulation produced intense fluorescent signal (Fig. 7Ci), while IL-8 promoter reporter 
358 output (GFP) was dampened by miR-146a-NPs (Fig. 7Cii). 
359 
 
360 4. Discussion 
361 4.1. Optimization of cationic NPs 
The data presented in this study indicate that PGA-co-PDL mixed with DOTAP 
formed cationic NPs using 10 % to 25 % (w/w) DOTAP. It was noted that increasing 
the concentration of DOTAP decreased particle size and caused the zeta potential to 
365 become more positive (Fig. 1A). This data agrees with previous research indicating 
366 that the use of DOTAP during particle preparation affects the particle size. Jensen et 
367 al. used DOTAP with PLGA for siRNA delivery, and reported that particle size 
368 decreased from 260.8±14.1 nm to 207.7±0.1 nm after use of various DOTAP 
369 concentrations, included during preparation [15]. 
370 DOTAP has previously been used in other studies as a cationic material to 
371 modify polymeric NP properties such as particle size, charge and improve gene 
372 transfection [25]. DOTAP is thought to limit the enlargement of polymeric NPs due to 
373 its surfactant and condensation characteristics [15]. Another reason for the change in 
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374 particle size is that the cationic material has the ability to decrease interfacial tension 
375 between the particle surface and the aqueous phase during formation [26]. This is 
376 similar to the effect of PVA on particle size during preparation of NPs [27], where the 
377 particle size decreased due to an adequate amount of surfactant covering the surface 
378 of PGA-co-PDL NPs [20]. 
379 Furthermore, electrostatic interaction between the DOTAP cationic moiety, 
380 quaternary amine and the negatively charged PGA-co-PDL neutralises the PGA-co- 
381 PDL and the remaining amine groups cause the positive charge [28-30]. 
382 The particle surface charge is another important factor for miRNA adsorption 
383 and cellular uptake. This electrostatic surface charge affects the adsorption of miR- 
384 146a, and addition of negatively charged miR-146a lead to a slight charge reduction 
385 in cationic NPs. This could be attributed to the decreased surface area of cationic NPs 
386 and  ionic interactions [23, 31]. The charge of cationic NPs remained positive after 
387 miR-146a adsorption, and the amount of miR-146a adsorbed on cationic NPs  over 
388 different time points indicated that the surface of cationic NPs was saturated with miR- 
389 146a after 2 h (Fig. 1B-D). 
390 
391 4.2. In vitro release 
392 The in vitro release of miR-146a from 15 % DOTAP NPs is affected by the 
393 presence of DOTAP in NPs. Cationic DOTAP has a quaternary amine group that 
394 provides opportunity of intermolecular hydrogen bonding with PVA and PGA-co-PDL, 
395 so DOTAP forms a network on the particle’s surface which affects miR-146a release. 
396 A similar study with surface adsorbed siRNA revealed, the in vitro release of siRNA 
397 from cationic PLGA was more than 60 % over 24 h [32] whereas in our study more 
398 than 70 % miR-146a was released from cationic NPs after 24 h. This could be related 
399 to PGA-co-PDL degrading slower than PLGA [33]. Kunda et al. conducted a similar in 
400 vitro release study using PGA-co-PDL NPs adsorbed BSA protein, and found that 
401 more than 90 % of BSA was released because of weaker hydrophobic interactions 
402 between BSA and NPs [20]. 
403 The in vitro release of miR-146a after 24 h was 77±1.5 %, which correlated 
404 with the change in gene silencing and protein levels indicated in the Western Blot data 
405 (Fig. 7B), suggesting that miR-146a maintained its biological efficacy and was not 
406 affected by the degradation of NPs. The protein level bands were intense at lower 
407 miR-146a-NPs concentration and the bands of intensity decreased when NPs 
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408 concentration is increased. The difference in protein level bands indicate that miR- 
409 146a-NPs produce intense bands which indicates a slight decrease in protein level, 
410 whereas the less intense band caused a significant decrease in protein levels, which 
411 will be discussed further in Western Blot data. A similar study by Li et al. using DOTAP 
412 as a cationic lipid to modify single-walled carbon nanotube as non-viral siRNA delivery 
413 system, found that cationic DOTAP electrostatically interact with negatively charged 
414 siRNA, protecting siRNA against degradation, and was released from single-walled 
415 carbon nanotube-DOTAP, realising its gene silencing potential in the cancer cells [34, 
416 35]. 
417 
418 4.3. Cytotoxicity studies and cellular uptake 
419 The concentration of optimum 15 % DOTAP NPs caused changes in A549 cell 
420 viability ranging from 77 – 64 % at 0.156 – 1.25 mg/ml (Fig. 4). Cells exposed to NPs 
421 without DOTAP had 96 % viability at 0.312 mg/ml, which decreased to 77 % with 15 % 
422 DOTAP NPs at 0.312 mg/ml and 64 % at 1.25 mg/ml. Although the data suggests a 
423 decrease in viability ranging from 77 – 64 %, the data obtained is with high particle 
424 concentration in a relatively small surface area (i.e. in a 96 well plate), whereas in the 
425 lungs, the surface area is significantly larger and the NPs will be more dispersed, thus 
426 the high level of NPs toxicity shown here is unlikely to be seen in a physiological setting 
427 [13]. Bose et al. also found that different DOTAP concentrations, when added to lipid 
428 polymer hybrid nanospheres, affected cell viability of various cell types (HEK293, 
429 HeLa, HaCaT, and HepG2) but did not cause severe cytotoxicity (cell viability was > 
430 70 % for all cell types) [23]. In addition, similar to our findings, Jensen et al. 
431 demonstrated the cell viability of H1229 cells was PLGA NPs and DOTAP 
432 concentration dependent with cell viability in the range of 65-70 % for 15 % DOTAP- 
433 containing NPs [15]. 
434 Nile Red NP were used to show the ability of cationic NPs cellular uptake and 
435 to deliver miR-146a to the cell. The uptake of PGA-co-PDL polymer based NPs had 
436 previously demonstrated in A549 [13] and dendritic cells [17]. Conventionally, miRNA 
437 are very limited in their ability to cross the cellular membrane, without use of polymer 
438 based carrier drug delivery system [36]. The cationic NPs, with adsorbed miR-146a, 
439 were distributed in cytoplasm and at periphery of the nucleus region in A549 lung 
440 fibroblasts. This distribution of FAM labelled miR-146a suggest that miR-146a could 
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441 interact with RISC complex with AGO2 and target mRNA in cytoplasm and achieve a 
442 good level of gene silencing [37, 38] . 
443 
444 4.4.Functional evaluation of miR-146a-loaded NPs on target gene, 
445 protein expression and reporter assay 
The functional activity of miR-146a loaded NPs, was assessed on miR-146a 
target gene, IRAK1. Early work by Baltimore and colleagues indicated that miR-146a 
448 inhibits the expression of IRAK1 genes and the significant function of miR-146a as 
449 negative regulator of inflammation [11]. The reduced target gene IRAK1 of miR-146a- 
450 NPs suggest that NPs delivered miR-146a to site of action and produced the expected 
451 downregulation effect (Fig. 7A). Assessment of the impact of the miR-146a-NPs on 
452 IRAK1 protein levels revealed protein band intensity decreased when the NPs’ 
453 concentration was further increased, suggesting that NPs delivered miR-146a to site 
454 of action (Fig. 7B). These functional studies confirm that miR-146a-NPs delivered to 
455 site of action in the lung cell lines, and miR-146a have modulated both genes and 
456 protein levels [39]. With these results, miR-146a-NPs appeared to be a promising 
457 therapeutic approach for treatment of disease by targeting genes products associated 
458 with inflammation. 
459 The effect of miR-146a-NPs in the expression of target gene IRAK1, protein 
460 levels, pIL-8 promoter reporter assay was used (Fig. 7C). Several studies have shown 
461 that miR-146a targets IRAK1 and TRAF6 in the IL-1R/TLR pathways that activate the 
462 NF-кB [10, 11, 40]. Using a fluorescent NF-кB responsive reporter, we showed that 
463 miR-146a-NPs impaired cytokine-dependent activation of NF-кB IN A549 cells. Hence, 
464 the ability of miR-146a-NPs to suppress IRAK1 translated into reduced activation of 
465 NF-кB and may thus ameliorate inflammatory processes associated with COPD. 
466 However, evaluation of the miR-146a-NPs in patient-derived COPD alveolar cells in 
467 monolayer and three-dimensional cultures will be required to demonstrate the full 
468 clinical potential of miR-146a-NPs. In human alveolar epithelial lung cells miR-146a 
469 reduced expression of IRAK1 [9]. 
470  
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471 5. Conclusion 
472 The cationic DOTAP was successfully used to produce cationic NPs with 
473 particle size 244.8±4.4 nm, which was similar to unloaded NPs 242.4±0.3 nm. 
474 Moreover, cationic NPs offer positive surface charge for miR-146a adsorption. The 
475 miR-146a adsorption was 32.25±2.0 µg miR-146a per 10 mg NPs after 2 h (the 
476 optimum conditions were 15 % DOTAP and miR146a adsorbed after 2 h). The in vitro 
477 release of miR-146a after 24 h was 77±1.5 %, the NPs were taken up by the cells and 
478 delivered miR-146a into the cell. 
479 The miR-146a maintained its functional structure under gene silencing and 
480 protein  level.  The  high  miR-146a-NPs  concentration  reduced  target  gene IRAK1 
481 expression to 40 %. The miR-146a-NPs reduced IL-8 promoter reporter GFP via IL- 
482 1β signalling pathway suggestion that miR-146a-NPs can be used to target proteins, 
483 regulate the inflammatory process. These successful studies and results show the 
484 potential of cationic NPs for delivery of miR-146a in the treatment and management 
485 of COPD. 
486  
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Figure 1 (A) The effect of the concentration of DOTAP on particle size of PGA-co- 
PDL NPs, (B) The effect of the concentration of DOTAP on the particle surface charge 
of PGA-co-PDL NPs, (C) Adsorption of miRNA (40 µg/ml) at different time points up 
to 24 h onto 15 % DOTAP NPs, (D) miRNA adsorption onto 15 % DOTAP NPs at 
various miRNA concentrations over 2 h, µg miRNA per 10 mg NPs. Data is 
represented in (A) and (B) as Mean ± SD (n=3), (C) and (D) as Mean ± SD (n=2). *p 
<0.05, ANOVA/ Tukey’s comparison. 
 
 
Figure 2. Image (A) shows red colour NPs (Nile Red dye), (B) the labelled FAM- 
miRNA (Green) and (C) the merged image of both A and B (scale bar represent 50 
µm). 
 
 
Figure 3. miRNA in vitro release from 15 % DOTAP NPs in phosphate buffer saline at 
pH 7.4. Data presented as Mean ± SD (n=3). 
 
Figure 4. Cytotoxic effect of unloaded NPs (0 % DOTAP) and 15 % DOTAP NPs on 
A549 cells after 18 h incubation. DMSO was used as positive control; the cell viability 
was measured using MTT assay. The experiments were repeated three times and 
data represented as mean ± SD (n=3), *p<0.05, ANOVA/Tukey’s to compare NPs with 
and without DOTAP at concentrations (0.312 mg, 0.625 mg, and 1.25 mg/ml) 
 
Figure 5. Fluorescence (A–C) and confocal (D–F) images of Nile Red NPs in A549 
cells after 1 h of incubation. (A&D) Nucleus is stained with DAPI, (B&E) NPs stained 
with Nile Red dye and (C&F) merged image. The scale bar represent 20 µm. 
 
Figure 6. Fluorescence (A–C) and confocal (D–F) images of FAM-labelled miR-146a- 
NPs in A549 Cells after 1 h of incubation. (A&D) Nucleus is stained with DAPI, (B&E) 
FAM-labelled miR-146a-NPs and (C&F) merged image. The scale bar represent 20 
µm. 
  
Figure 7. (A) Effect of miR-146a loaded NPs on IRAK1 expression. The highest two 
concentrations were pooled from the three independent experiments. The expression 
of IRAK1 was normalised to GAPDH expression. Data represented as Mean ± SD 
(n=3). (B) Effect of miR-146a on IRAK1 protein levels in A549 cells. Dark triangle 
represents lowest (left) to highest (right) miR-146a-NPs concentrations. The numbers 
under each band represents the densitometric readings relative to control samples 
normalized to each band and to its corresponding β-actin control. Fluorescence 
images of (Ci) response of pIL8 reporter to cells stimulated with IL-1β, (Cii) Cells 
loaded with miR-146a-NPs prior to stimulation with IL-1β. The scale bar represent 20 
μm. 
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